DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center

Mirella Salvatore(Cornell University), Rosemary Soave(Cornell University), Koen van Besien(University Hospitals of Cleveland), Tsiporah B. Shore(Cornell University), Audrey N. Schuetz(Mayo Clinic), Ronald B. Moss(Vical (United States)), Michael J. Satlin(Cornell University), Stephen G. Jenkins(NewYork–Presbyterian Hospital), Samantha E. Jacobs(University of Pennsylvania)
Transplantation and Cellular Therapy
February 22, 2016
10.1016/j.bbmt.2016.02.011
Cited by 64

Related Papers

Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
|Clinical Infectious Diseases|2016|3k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter
|American Journal of Transplantation|2020|837